AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29517567 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacotherapy
Number of subjects: 459
Study 29517567 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of contacts with a tobacco quitline
Number of subjects: 459
Study 29517567 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of other smokers in the household
Number of subjects: 459
Study 29517567 — intervention group
Group type: EXPERIMENTAL
Intervention: Amount spent on cigarettes weekly at baseline (per $10 increase)
Number of subjects: 459
Study 29518185 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline gut microbiome characterized by Proteobacteria
Number of subjects: 199
Study 29518185 — intervention group
Group type: EXPERIMENTAL
Intervention: Enterococcaceae dominance (relative abundance ≥30%)
Number of subjects: 199
Study 29518185 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptococcaceae dominance
Number of subjects: 199
Study 29518185 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbial diversity after induction and reinduction phases of chemotherapy
Number of subjects: 199
Study 29518185 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative abundance of certain bacterial taxa (Bacteroidetes)
Number of subjects: 199
Study 29518185 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative abundance of other taxa (Clostridiaceae and Streptococcaceae)
Number of subjects: 199
Study 29518528 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive meditation retreat
Number of subjects: 0
Study 29518528 — intervention group
Group type: COMPARATOR
Intervention: Control group of experienced meditators
Number of subjects: 0
Study 29518553 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab (240 mg every 2 weeks) plus Crizotinib (250 mg twice daily)
Number of subjects: 13
Study 29519282 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual chest compression, electric defibrillation, or epinephrine ≤ 4 mg
Number of subjects: 613
Study 29519282 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital cardiac arrest (IHCA)
Number of subjects: 613
Study 29519282 — intervention group
Group type: EXPERIMENTAL
Intervention: Age < 65 years, witnessed CPR, manual chest compression, electric defibrillation, or epinephrine ≤ 4 mg
Number of subjects: 613
Study 29519282 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulance CA
Number of subjects: 613
Study 29519282 — intervention group
Group type: EXPERIMENTAL
Intervention: Total adrenaline ≤ 4 mg
Number of subjects: 613
Study 29519540 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatoportoenterostomy (successful)
Number of subjects: 148
Study 29519540 — intervention group
Group type: COMPARATOR
Intervention: Hepatoportoenterostomy (unsuccessful)
Number of subjects: 148
Study 29519540 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurodevelopmental testing using Bayley Scales of Infant Development
Number of subjects: 148
Study 29519540 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascites
Number of subjects: 148
Study 29519540 — intervention group
Group type: EXPERIMENTAL
Intervention: Low length z-scores
Number of subjects: 148
Study 29519540 — intervention group
Group type: EXPERIMENTAL
Intervention: Low weight z-scores
Number of subjects: 148
Study 29519776 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative interactive e-learning multimedia (IM) module
Number of subjects: 24
Study 29519776 — intervention group
Group type: COMPARATOR
Intervention: Conventional PowerPoint show (PPS) module
Number of subjects: 24
Study 29519811 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity troponin I (hsTnI) concentrations measured using a single-molecule counting assay (99th percentile, 6 ng/L)
Number of subjects: 991
Study 29519811 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sensitivity troponin I (hsTnI) concentrations
Number of subjects: 991
Study 29519879 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for retinopathy of prematurity (ROP)
Number of subjects: 6115
Study 29519879 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening of infants with a GA≤34 weeks or a BW<1700 g
Number of subjects: 6115
Study 29519879 — intervention group
Group type: EXPERIMENTAL
Intervention: Independent risk factors for severe ROP in infants with a BW≤1500 g
Number of subjects: 6115
Study 29519879 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall incidence of ROP
Number of subjects: 6115
Study 29519879 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment criteria
Number of subjects: 6115
Study 29519925 — intervention group
Group type: EXPERIMENTAL
Intervention: Polysomnography (PSG) assessment of sleep alterations
Number of subjects: 45
Study 29520431 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary stenting with nitinol self-expanding stents
Number of subjects: 100
Study 29520431 — intervention group
Group type: COMPARATOR
Intervention: Best medical treatment (BMT) alone
Number of subjects: 100
Study 29520615 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabeloop Artificial Pancreas system with customized settings and remote monitoring
Number of subjects: 8
Study 29520615 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote monitoring by expert nurses with a web platform generating automatic Secured Information Messages (SIMs)
Number of subjects: 8
Study 29522089 — intervention group
Group type: EXPERIMENTAL
Intervention: Artemisinin-based combination therapy
Number of subjects: 2399
Study 29522186 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic insomnia
Number of subjects: 12
Study 29522186 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold pressor test
Number of subjects: 12
Study 29522186 — intervention group
Group type: COMPARATOR
Intervention: Good-sleeper controls
Number of subjects: 12
Study 29522222 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic insomnia patients
Number of subjects: 30
Study 29522222 — intervention group
Group type: COMPARATOR
Intervention: Matched good sleepers
Number of subjects: 30
Study 29522361 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-only metastatic breast cancer (BO MBC)
Number of subjects: 10521
Study 29523117 — intervention group
Group type: EXPERIMENTAL
Intervention: Insomnia Severity Index (ISI)
Number of subjects: 300
Study 29523117 — intervention group
Group type: EXPERIMENTAL
Intervention: Berlin Questionnaire (BQ)
Number of subjects: 300
Study 29523117 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic medical records for insomnia
Number of subjects: 300
Study 29523117 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic medical records for OSA
Number of subjects: 300
Study 29523117 — intervention group
Group type: EXPERIMENTAL
Intervention: Characteristics associated with insomnia
Number of subjects: 300
Study 29523117 — intervention group
Group type: EXPERIMENTAL
Intervention: Characteristics associated with OSA
Number of subjects: 300
Study 29523147 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-linolenic acid (LNA; omega-3) intake
Number of subjects: 352
Study 29523147 — intervention group
Group type: EXPERIMENTAL
Intervention: Linoleic acid (LA; omega-6) intake
Number of subjects: 352
Study 29523147 — intervention group
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid (EPA; omega-3) intake
Number of subjects: 352
Study 29523147 — intervention group
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA; omega-3) intake
Number of subjects: 352
Study 29523147 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-6 to omega-3 ratios
Number of subjects: 352
Study 29523147 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet quality
Number of subjects: 352
Study 29523147 — intervention group
Group type: EXPERIMENTAL
Intervention: Education level in adults
Number of subjects: 352
Study 29523153 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal life support (ECLS) treatment
Number of subjects: 210
Study 29523153 — intervention group
Group type: EXPERIMENTAL
Intervention: ECLS treatment
Number of subjects: 210
Study 29523169 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile application (App My eReport France®) introduced by a neurologist to report adverse drug reactions (ADR).
Number of subjects: 180
Study 29523169 — intervention group
Group type: COMPARATOR
Intervention: Control group informed of the existence of the App but not introduced to its use, reporting ADR according to usual procedures.
Number of subjects: 180
Study 29523171 — intervention group
Group type: EXPERIMENTAL
Intervention: Umbilical cord mesenchymal stem cells (UCMSC) intravenous infusions, 7 infusions of 20 × 10^6 cells each.
Number of subjects: 20
Study 29523171 — intervention group
Group type: EXPERIMENTAL
Intervention: UCMSC intravenous infusions
Number of subjects: 20
Study 29523524 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorthalidone (thiazide-like diuretic)
Number of subjects: 310
Study 29523908 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel wound retractor combining continuous irrigation and barrier protection
Number of subjects: 86
Study 29523993 — intervention group
Group type: EXPERIMENTAL
Intervention: mGCL in perimetric group
Number of subjects: 212
Study 29523993 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNFL in perimetric group
Number of subjects: 212
Study 29523993 — intervention group
Group type: EXPERIMENTAL
Intervention: mGCC in perimetric group
Number of subjects: 212
Study 29523993 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNFL in HT perimetric group
Number of subjects: 212
Study 29523993 — intervention group
Group type: EXPERIMENTAL
Intervention: pRNFL in HT perimetric group
Number of subjects: 212
Study 29523993 — intervention group
Group type: EXPERIMENTAL
Intervention: mRNFL in NT groups
Number of subjects: 212
Study 29523993 — intervention group
Group type: EXPERIMENTAL
Intervention: mGCL and mRNFL
Number of subjects: 212
Study 29524090 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertensive group
Number of subjects: 201
Study 29524090 — intervention group
Group type: COMPARATOR
Intervention: Normotensive group
Number of subjects: 201
Study 29524759 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-release dimethyl fumarate (DMF)
Number of subjects: 506
Study 29524918 — intervention group
Group type: EXPERIMENTAL
Intervention: Working memory task with emotional distractors (happy and fearful) during 2-back task
Number of subjects: 20
Study 29524918 — intervention group
Group type: EXPERIMENTAL
Intervention: fMRI analysis of brain activity in left IFG (BA 45)
Number of subjects: 20
Study 29524918 — intervention group
Group type: COMPARATOR
Intervention: Working memory task with emotional distractors (happy and fearful) during 0-back task
Number of subjects: 20
Study 29524918 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training for emotion regulation
Number of subjects: 20
Study 29525290 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-enhanced intervention
Number of subjects: 193
Study 29525290 — intervention group
Group type: COMPARATOR
Intervention: Active cognitive-behavioral weight loss intervention
Number of subjects: 193
Study 29525512 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioimpedance analysis (BIA)
Number of subjects: 200
Study 29525512 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up at 6 and 12 months
Number of subjects: 200
Study 29525541 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemohormonal therapy
Number of subjects: 0
Study 29525541 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 29525724 — intervention group
Group type: EXPERIMENTAL
Intervention: Invasive strategy (coronary angiogram and revascularization if anatomically amenable)
Number of subjects: 178
Study 29525724 — intervention group
Group type: COMPARATOR
Intervention: Conservative strategy (medical treatment and coronary angiogram only if persistent clinical instability)
Number of subjects: 178
Study 29525775 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualised, supervised exercise (six weekly sessions)
Number of subjects: 0
Study 29525782 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest pain units
Number of subjects: 2520
Study 29526614 — intervention group
Group type: EXPERIMENTAL
Intervention: Elosulfase alfa 0.1 mg/kg/week
Number of subjects: 20
Study 29526614 — intervention group
Group type: EXPERIMENTAL
Intervention: Elosulfase alfa 1.0 mg/kg/week
Number of subjects: 20
Study 29526614 — intervention group
Group type: EXPERIMENTAL
Intervention: Elosulfase alfa 2.0 mg/kg/week
Number of subjects: 20
Study 29526614 — intervention group
Group type: EXPERIMENTAL
Intervention: Elosulfase alfa (home infusions)
Number of subjects: 20
Study 29526614 — intervention group
Group type: EXPERIMENTAL
Intervention: Elosulfase alfa (overall)
Number of subjects: 20
Study 29526687 — intervention group
Group type: EXPERIMENTAL
Intervention: Venous pressure gradients (VPGs)
Number of subjects: 50
Study 29526687 — intervention group
Group type: EXPERIMENTAL
Intervention: FCG-rh (femorocaval gradient after reactive hyperemia)
Number of subjects: 50
Study 29526687 — intervention group
Group type: EXPERIMENTAL
Intervention: Femoral vein pressures at rest and after reactive hyperemia
Number of subjects: 50
Study 29526687 — intervention group
Group type: EXPERIMENTAL
Intervention: Logistic regression analysis of FCG-rh
Number of subjects: 50
Study 29527010 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib (200 mg BID) plus FOLFIRI (without 5-fluorouracil bolus)
Number of subjects: 92
Study 29527010 — intervention group
Group type: EXPERIMENTAL
Intervention: Veliparib (10-270 mg BID, days 1-5, 15-19) and FOLFIRI (days 1-3, 15-17)
Number of subjects: 92
Study 29527350 — intervention group
Group type: EXPERIMENTAL
Intervention: mCME V.2.0 intervention (daily SMS quizzes, readings, online CME links, feedback)
Number of subjects: 106
Study 29527350 — intervention group
Group type: EXPERIMENTAL
Intervention: mCME V.2.0 intervention
Number of subjects: 106
Study 29527350 — intervention group
Group type: COMPARATOR
Intervention: Control group (equal access to online CME courses)
Number of subjects: 106
Study 29527350 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 106
Study 29527358 — intervention group
Group type: EXPERIMENTAL
Intervention: Centrally produced ready-to-use therapeutic food
Number of subjects: 906
Study 29527358 — intervention group
Group type: EXPERIMENTAL
Intervention: Locally produced ready-to-use therapeutic food
Number of subjects: 906
Study 29527358 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmented, energy-dense, home-prepared food
Number of subjects: 906
Study 29527644 — intervention group
Group type: EXPERIMENTAL
Intervention: Make Safe Happen® app
Number of subjects: 0
Study 29527644 — intervention group
Group type: COMPARATOR
Intervention: Non-injury-related app
Number of subjects: 0
Study 29527652 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung ultrasound
Number of subjects: 62
Study 29527652 — intervention group
Group type: COMPARATOR
Intervention: Chest X-ray
Number of subjects: 62
Study 29528048 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker-guided treatment shortening
Number of subjects: 0
Study 29528048 — intervention group
Group type: COMPARATOR
Intervention: Standard TB treatment
Number of subjects: 0
Study 29528727 — intervention group
Group type: EXPERIMENTAL
Intervention: B vitamin intake assessment through 24-hour dietary recalls
Number of subjects: 0
Study 29528761 — intervention group
Group type: EXPERIMENTAL
Intervention: Raman spectroscopy of PBMCs
Number of subjects: 48
Study 29529007 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary AKI biomarkers (TIMP-2*IGFBP-7 ≥0.78 at 12 hours)
Number of subjects: 94
Study 29529007 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary AKI biomarkers (KIM-1 ≥529.57 at 24 hours)
Number of subjects: 94
Study 29529007 — intervention group
Group type: EXPERIMENTAL
Intervention: Milrinone clearance in patients with AKI
Number of subjects: 94
Study 29529007 — intervention group
Group type: EXPERIMENTAL
Intervention: Excessive milrinone activity
Number of subjects: 94
Study 29529091 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramadan fasting (RF) with aspirin
Number of subjects: 177
Study 29529091 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-DM patients)
Number of subjects: 177
Study 29529139 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortified human milk
Number of subjects: 32
Study 29529147 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-risk participants (AA genotype)
Number of subjects: 114
Study 29529156 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (≥400 µg/d)
Number of subjects: 563
Study 29529156 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (elevated plasma folate)
Number of subjects: 563
Study 29529156 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation
Number of subjects: 563
Study 29529162 — intervention group
Group type: EXPERIMENTAL
Intervention: Cereal fiber
Number of subjects: 117885
Study 29529162 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-to-cereal fiber ratio
Number of subjects: 117885
Study 29529162 — intervention group
Group type: EXPERIMENTAL
Intervention: Starch-to-cereal fiber ratio
Number of subjects: 117885
Study 29529162 — intervention group
Group type: EXPERIMENTAL
Intervention: Total fiber intake
Number of subjects: 117885
Study 29529162 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-to-total fiber ratio
Number of subjects: 117885
Study 29529162 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quintile of carbohydrate intake
Number of subjects: 117885
Study 29529177 — intervention group
Group type: EXPERIMENTAL
Intervention: Performed revascularization
Number of subjects: 1334
Study 29529177 — intervention group
Group type: COMPARATOR
Intervention: Deferred revascularization
Number of subjects: 1334
Study 29530029 — intervention group
Group type: EXPERIMENTAL
Intervention: Canadian CT Head Rule (CCHR) presentation
Number of subjects: 167
Study 29530029 — intervention group
Group type: EXPERIMENTAL
Intervention: Malpractice review information
Number of subjects: 167
Study 29530029 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient cost information
Number of subjects: 167
Study 29530029 — intervention group
Group type: COMPARATOR
Intervention: Initial imaging orders
Number of subjects: 167
Study 29530053 — intervention group
Group type: COMPARATOR
Intervention: Neural stimulation system active during simulated collision events
Number of subjects: 7
Study 29530053 — intervention group
Group type: COMPARATOR
Intervention: Neural stimulation system active during simulated rapid turns
Number of subjects: 7
Study 29530053 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural stimulation system inactive (subjects acting as their own controls)
Number of subjects: 7
Study 29530274 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiovascular risk factors (CVRF) assessment
Number of subjects: 410
Study 29530274 — intervention group
Group type: EXPERIMENTAL
Intervention: Dyslipidaemia prevalence
Number of subjects: 410
Study 29530274 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension prevalence
Number of subjects: 410
Study 29530274 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes prevalence
Number of subjects: 410
Study 29530274 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking prevalence
Number of subjects: 410
Study 29530274 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal obesity prevalence
Number of subjects: 410
Study 29530274 — intervention group
Group type: EXPERIMENTAL
Intervention: Body mass index (BMI) ≥30kg/m prevalence
Number of subjects: 410
Study 29530544 — intervention group
Group type: EXPERIMENTAL
Intervention: tedizolid phosphate 200 mg, once-daily for 7-14 days
Number of subjects: 125
Study 29530544 — intervention group
Group type: COMPARATOR
Intervention: linezolid 600 mg, twice-daily for 7-14 days
Number of subjects: 125
Study 29530544 — intervention group
Group type: EXPERIMENTAL
Intervention: tedizolid phosphate 200 mg, once-daily
Number of subjects: 125
Study 29530544 — intervention group
Group type: COMPARATOR
Intervention: linezolid 600 mg, twice-daily
Number of subjects: 125
Study 29530644 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong recommendations with evidence summaries
Number of subjects: 467
Study 29530644 — intervention group
Group type: EXPERIMENTAL
Intervention: Weak recommendations with evidence summaries
Number of subjects: 467
Study 29530644 — intervention group
Group type: COMPARATOR
Intervention: Evidence summaries alone
Number of subjects: 467
Study 29530644 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong recommendations
Number of subjects: 467
Study 29530667 — intervention group
Group type: EXPERIMENTAL
Intervention: Avelumab 10 mg/kg intravenously every 2 weeks and axitinib 5 mg orally twice daily
Number of subjects: 55
Study 29530726 — intervention group
Group type: EXPERIMENTAL
Intervention: AbobotulinumtoxinA
Number of subjects: 304
Study 29530837 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical procedures with Staphylococcus aureus SSI
Number of subjects: 150000
Study 29530855 — intervention group
Group type: EXPERIMENTAL
Intervention: Doripenem administration during dialysis
Number of subjects: 0
Study 29530855 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-hemodialysis dosing of Doripenem
Number of subjects: 0
Study 29530914 — intervention group
Group type: EXPERIMENTAL
Intervention: MSD intervention consisting of 2-hour class sessions over a 13-week period
Number of subjects: 320
Study 29530914 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 320
Study 29530935 — intervention group
Group type: EXPERIMENTAL
Intervention: Trastuzumab treatment
Number of subjects: 0
Study 29530989 — intervention group
Group type: EXPERIMENTAL
Intervention: First Blood Pressure Measurement (fBPM)
Number of subjects: 1000
Study 29530989 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term masked hypertension (STMH)
Number of subjects: 1000
Study 29530989 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term white coat hypertension (STWCH)
Number of subjects: 1000
Study 29531316 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide/RCHOP
Number of subjects: 427
Study 29531316 — intervention group
Group type: COMPARATOR
Intervention: RCHOP alone
Number of subjects: 427
Study 29531316 — intervention group
Group type: EXPERIMENTAL
Intervention: Real-time ECPR
Number of subjects: 427
Study 29531316 — intervention group
Group type: COMPARATOR
Intervention: Retrospective ECPR
Number of subjects: 427
Study 29531316 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-ECPR
Number of subjects: 427
Study 29531651 — intervention group
Group type: EXPERIMENTAL
Intervention: Elotuzumab in combination with lenalidomide and dexamethasone (ELd)
Number of subjects: 0
Study 29531651 — intervention group
Group type: COMPARATOR
Intervention: Lenalidomide and dexamethasone (Ld)
Number of subjects: 0